Prognostic factors associated with complete cytogenetic response (n = 256) and with survival (n = 261)
Characteristic . | No. . | No. with complete cytogenetic response (%) . | P . | Estimated 4-y survival, % . | P . |
|---|---|---|---|---|---|
| Age, y | |||||
| Younger than 60 | 169 | 113 (67) | .13 | 90 | .06 |
| 60 or older | 87 | 49 (56) | .13 | 81 | |
| Last response to IFN-α | |||||
| Hematologic resistance | 22 | 7 (32) | < .01 | 62 | < .01 |
| Hematologic relapse | 13 | 7 (54) | 82 | ||
| Cytogenetic resistance | 74 | 37 (50) | 93 | ||
| Cytogenetic relapse | 52 | 47 (90) | 92 | ||
| IFN-α intolerance | 95 | 64 (67) | 85 | ||
| Splenomegaly, cm bcm | |||||
| 0 | 228 | 152 (67) | .01 | 90 | < .01 |
| 1 to 9 | 21 | 7 (33) | 60 | ||
| 10 or more | 6 | 3 (50) | 50 | ||
| Mos from diagnosis to therapy | |||||
| Less than 12 | 27 | 21 (78) | .26 | 86 | .59 |
| 12 to 35 | 109 | 67 (61) | 88 | ||
| 36 or more | 120 | 74 (62) | 85 | ||
| Hemoglobin level, g/dL | |||||
| Less than 10 | 16 | 7 (44) | .24 | 68 | .07 |
| 10 to 11.9 | 83 | 53 (64) | 88 | ||
| 12 or more | 157 | 102 (65) | 88 | ||
| White blood cell count | |||||
| Less than 10 × 109/L | 130 | 99 (76) | < .01 | 92 | .01 |
| 10 to 50 × 109/L | 102 | 52 (51) | 83 | ||
| More than 50 × 109/L | 24 | 11 (46) | 71 | ||
| Platelet count | |||||
| 450 × 109/L or less | 197 | 139 (71) | < .01 | 90 | .01 |
| 451 × 109/L to 700 × 109/L | 38 | 15 (39) | 78 | ||
| More than 700 × 109/L | 21 | 8 (38) | 67 | ||
| Peripheral blasts | |||||
| 0% | 211 | 145 (69) | < .01 | 91 | < .01 |
| 1% or 2% | 36 | 14 (39) | 71 | ||
| 3% or more | 9 | 3 (33) | 44 | ||
| Marrow blasts | |||||
| Less than 5% | 231 | 154 (67) | < .01 | 89 | < .01 |
| 5% or more | 25 | 8 (32) | 64 | ||
| Peripheral basophils | |||||
| Less than 7% | 226 | 151 (67) | < .01 | 88 | .03 |
| 7% or more | 30 | 11 (37) | 71 | ||
| Marrow basophils | |||||
| Less than 5% | 223 | 148 (66) | .01 | 89 | < .01 |
| 5% or more | 33 | 14 (42) | 70 | ||
| % Ph + cells at start of therapy | |||||
| 90 or less | 67 | 62 (93) | < .01 | 94 | .03 |
| More than 90 | 187 | 98 (52) | 84 | ||
| Clonal evolution | |||||
| No | 232 | 152 (66) | .03 | 88 | < .01 |
| Yes | 24 | 10 (42) | 69 | ||
| Hasford model | |||||
| Low | 59 | 43 of 57 (75) | .19 | 91 | .07 |
| Intermediate | 48 | 27 of 46 (59) | 93 | ||
| High | 8 | 5 (63) | 75 |
Characteristic . | No. . | No. with complete cytogenetic response (%) . | P . | Estimated 4-y survival, % . | P . |
|---|---|---|---|---|---|
| Age, y | |||||
| Younger than 60 | 169 | 113 (67) | .13 | 90 | .06 |
| 60 or older | 87 | 49 (56) | .13 | 81 | |
| Last response to IFN-α | |||||
| Hematologic resistance | 22 | 7 (32) | < .01 | 62 | < .01 |
| Hematologic relapse | 13 | 7 (54) | 82 | ||
| Cytogenetic resistance | 74 | 37 (50) | 93 | ||
| Cytogenetic relapse | 52 | 47 (90) | 92 | ||
| IFN-α intolerance | 95 | 64 (67) | 85 | ||
| Splenomegaly, cm bcm | |||||
| 0 | 228 | 152 (67) | .01 | 90 | < .01 |
| 1 to 9 | 21 | 7 (33) | 60 | ||
| 10 or more | 6 | 3 (50) | 50 | ||
| Mos from diagnosis to therapy | |||||
| Less than 12 | 27 | 21 (78) | .26 | 86 | .59 |
| 12 to 35 | 109 | 67 (61) | 88 | ||
| 36 or more | 120 | 74 (62) | 85 | ||
| Hemoglobin level, g/dL | |||||
| Less than 10 | 16 | 7 (44) | .24 | 68 | .07 |
| 10 to 11.9 | 83 | 53 (64) | 88 | ||
| 12 or more | 157 | 102 (65) | 88 | ||
| White blood cell count | |||||
| Less than 10 × 109/L | 130 | 99 (76) | < .01 | 92 | .01 |
| 10 to 50 × 109/L | 102 | 52 (51) | 83 | ||
| More than 50 × 109/L | 24 | 11 (46) | 71 | ||
| Platelet count | |||||
| 450 × 109/L or less | 197 | 139 (71) | < .01 | 90 | .01 |
| 451 × 109/L to 700 × 109/L | 38 | 15 (39) | 78 | ||
| More than 700 × 109/L | 21 | 8 (38) | 67 | ||
| Peripheral blasts | |||||
| 0% | 211 | 145 (69) | < .01 | 91 | < .01 |
| 1% or 2% | 36 | 14 (39) | 71 | ||
| 3% or more | 9 | 3 (33) | 44 | ||
| Marrow blasts | |||||
| Less than 5% | 231 | 154 (67) | < .01 | 89 | < .01 |
| 5% or more | 25 | 8 (32) | 64 | ||
| Peripheral basophils | |||||
| Less than 7% | 226 | 151 (67) | < .01 | 88 | .03 |
| 7% or more | 30 | 11 (37) | 71 | ||
| Marrow basophils | |||||
| Less than 5% | 223 | 148 (66) | .01 | 89 | < .01 |
| 5% or more | 33 | 14 (42) | 70 | ||
| % Ph + cells at start of therapy | |||||
| 90 or less | 67 | 62 (93) | < .01 | 94 | .03 |
| More than 90 | 187 | 98 (52) | 84 | ||
| Clonal evolution | |||||
| No | 232 | 152 (66) | .03 | 88 | < .01 |
| Yes | 24 | 10 (42) | 69 | ||
| Hasford model | |||||
| Low | 59 | 43 of 57 (75) | .19 | 91 | .07 |
| Intermediate | 48 | 27 of 46 (59) | 93 | ||
| High | 8 | 5 (63) | 75 |
bcm indicates below coastal margin.